Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on RD.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
No comments:
Post a Comment